John A Glaspy

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    CLINICAL EVALUATION OF BIOLOGICAL RESPONSE MODIFIERS
    NIH/NCI N01CM007439Sep 30, 1980
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021 Oct 08; 7(1):134. Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. PMID: 34625570; PMCID: PMC8501074.
      View in: PubMed   Mentions:
    2. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer. 2021 Oct; 9(10). Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ. PMID: 34599031; PMCID: PMC8488725.
      View in: PubMed   Mentions:    Fields:    
    3. A Randomized Phase 2 Study Of Nivolumab Monotherapy Or Nivolumab Combined with Ipilimumab In Patients with Advanced Gastrointestinal Stromal Tumors. Clin Cancer Res. 2021 Aug 18. Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M, Hagopian A, Andes R, Sauer L, Brackert SR, Chow W, DeMatteo R, Eilber FC, Glaspy JA, Chmielowski B. PMID: 34407970.
      View in: PubMed   Mentions: 1     Fields:    
    4. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther. 2021 07; 38(7):3531-3549. Glaspy JA, Wolf M, Strauss WE. PMID: 34053011.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204). Neuro Oncol. 2021 Apr 21. Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. PMID: 33880555.
      View in: PubMed   Mentions:    Fields:    
    6. Cost-Health Literacy as an Educational Objective in Fellowship Training. J Cancer Educ. 2021 Mar 24. Fischer KA, Anand S, Walling A, Larson SM, Glaspy J. PMID: 33761118.
      View in: PubMed   Mentions:    Fields:    
    7. Financial Toxicity From Generic Specialty Drug Use. JAMA Oncol. 2021 Feb 01; 7(2):175-176. Fischer KA, Miller RE, Glaspy JA. PMID: 33211083.
      View in: PubMed   Mentions: 1     Fields:    
    8. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States. Expert Rev Clin Pharmacol. 2021 Jan; 14(1):1-8. Anand S, Al-Mondhiry J, Fischer K, Glaspy J. PMID: 33307871.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. Am J Hematol. 2021 01; 96(1):E11-E15. Wolf M, Auerbach M, Kalra PA, Glaspy J, Thomsen LL, Bhandari S. PMID: 33027541.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Workup of anemia in cancer. Clin Adv Hematol Oncol. 2020 Oct; 18(10):640-646. Anand S, Burkenroad A, Glaspy J. PMID: 33201870.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020 08; 5(4). Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, Kouchakji E, Rocha F, Carrier E. PMID: 32817130.
      View in: PubMed   Mentions:
    12. A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial. Am J Hematol. 2020 Jun 29. Achebe MM, Glaspy J, Kalra PA, Auerbach M, Thomsen LL, Bhandari S. PMID: 32602177.
      View in: PubMed   Mentions: 1     Fields:    
    13. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review. Ther Clin Risk Manag. 2020; 16:245-259. Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV. PMID: 32308402.
      View in: PubMed   Mentions:
    14. Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity. Support Care Cancer. 2020 Dec; 28(12):5709-5715. Fischer KA, Walling A, Wenger N, Glaspy J. PMID: 32193693.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Establishing a Denominator for Palliative Care Quality Metrics for Patients with Advanced Cancer. J Palliat Med. 2020 09; 23(9):1239-1242. Anand S, Glaspy J, Roh L, Khandelwal V, Wenger N, Ritchie C, Walling AM. PMID: 31928372.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019 09; 94(9):1007-1014. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. PMID: 31243803.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    17. Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 06 01; 24(11):2493-2504. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH. PMID: 29476019.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    18. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 06 10; 36(17):1658-1667. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. PMID: 28981385.
      View in: PubMed   Mentions: 170     Fields:    Translation:HumansCellsCTClinical Trials
    19. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017 11; 25(11):3295-3304. Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. PMID: 28842778.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    20. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 05; 18(5):654-662. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. PMID: 28314691.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    21. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 06; 7(6):620-629. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. PMID: 28242752.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCellsCTClinical Trials
    22. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 08; 5(8):1897-907. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. PMID: 27334013.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    23. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016 Apr; 36(4):402-14. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. PMID: 26927900.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    24. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PMID: 26787823.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCellsCTClinical Trials
    25. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr; 24(4):1517-25. Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. PMID: 26370220.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    26. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. PMID: 26364516.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    27. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27; 515(7528):568-71. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PMID: 25428505.
      View in: PubMed   Mentions: 2029     Fields:    Translation:HumansCellsCTClinical Trials
    28. Iron deficiency anemia--bridging the knowledge and practice gap. Transfus Med Rev. 2014 Jul; 28(3):156-66. Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, Ghiglione M, Glaspy J, Lew I. PMID: 24931617.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    29. Current status of use of erythropoietic agents in cancer patients. Semin Thromb Hemost. 2014 Apr; 40(3):306-12. Glaspy J. PMID: 24676903.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    30. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. PMID: 24634374.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    31. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF. PMID: 24374975.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    32. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. PMID: 24265155.
      View in: PubMed   Mentions: 376     Fields:    Translation:HumansCells
    33. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202. Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR. PMID: 24417913.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    34. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013; 18(7):812-8. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ, Translational Research in Oncology BCIRG 006 Trial Investigators . PMID: 23814044.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    35. Chemotherapy-induced anemia: the story of darbepoetin alfa. Curr Med Res Opin. 2013 Apr; 29(4):325-37. Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M. PMID: 23323876.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C, TRIO/BCIRG 001 investigators . PMID: 23246022.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    37. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. PMID: 23171508.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    38. Update on safety of ESAs in cancer-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):659-66. Glaspy J. PMID: 22570294.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012 Jun; 76(3):478-85. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. PMID: 22277104.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    40. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. PMID: 22194965.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    41. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 06; 365(14):1273-83. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group . PMID: 21991949.
      View in: PubMed   Mentions: 725     Fields:    Translation:Humans
    42. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. PMID: 21609436.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    43. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK, Theratope® Study Group . PMID: 21572124.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    44. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. PMID: 21558401.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCellsCTClinical Trials
    45. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson. Oncology (Williston Park). 2011 Apr 30; 25(5):423-4. Glaspy JA. PMID: 21710839.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 01; 29(10):1252-60. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. PMID: 21383283.
      View in: PubMed   Mentions: 351     Fields:    Translation:HumansCTClinical Trials
    47. Randomized controlled trials of the erythroid-stimulating agents in cancer patients. Cancer Treat Res. 2011; 157:195-215. Glaspy JA. PMID: 21052958.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27; 8:89. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. PMID: 20875102.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    49. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15; 116(18):4227-37. Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. PMID: 20549829.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    50. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 2010 Aug; 12(8):637-49. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. PMID: 20689758.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    51. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. PMID: 20705564.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    52. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul; 122(1):181-8. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. PMID: 20361252.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    53. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19; 102(2):301-15. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. PMID: 20051958.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    54. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010 Jan 01; 116(1):146-54. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. PMID: 19862820.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    55. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009 Dec 01; 15(23):7116-8. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Ribas A, Chmielowski B, Glaspy JA. PMID: 19934296.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    56. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer. 2009 Nov 15; 115(22):5228-36. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY. PMID: 19728370.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    57. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. PMID: 19884534.
      View in: PubMed   Mentions: 234     Fields:    Translation:HumansCellsCTClinical Trials
    58. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. PMID: 19789309.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCellsCTClinical Trials
    59. Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. J Oncol Pract. 2009 Sep; 5(5):236-43. Naeim A, Friedman L, Whitlock KB, Pasta DJ, Elkin EP, Lubeck DP, Viswanathan HN, Glaspy J. PMID: 20856735.
      View in: PubMed   Mentions: 1     Fields:    
    60. Hematology: ESAs to treat anemia--balancing the risks and benefits. Nat Rev Clin Oncol. 2009 Sep; 6(9):500-2. Glaspy J. PMID: 19707239.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    61. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol. 2009 Jun 20; 27(18):2896-7. Glaspy J, Ribas A, Chmielowski B. PMID: 19433677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009 Jun 10; 27(17):2838-47. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. PMID: 19380447.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    63. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009 Mar 01; 115(5):1121-31. Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE. PMID: 19170225.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    64. Erythropoietin in cancer patients. Annu Rev Med. 2009; 60:181-92. Glaspy JA. PMID: 18980468.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    65. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. PMID: 19118070.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    66. Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw. 2008 Jul; 6(6):565-75. Glaspy JA. PMID: 18597710.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    67. Erythropoietins should be used according to guidelines. Lancet Oncol. 2008 May; 9(5):412-3. Aapro MS, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P. PMID: 18452853.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    68. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. PMID: 18452610.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    69. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. PMID: 18317358.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    70. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol. 2008 May; 19(5):833-4. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, Henry DH. PMID: 18369084.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    71. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 Mar 01; 26(7):1040-50. Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. PMID: 18227526.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    72. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. J Med Econ. 2008; 11(2):199-213. Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD. PMID: 19450080.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007 Oct; 12(10):1253-63. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. PMID: 17962619.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    74. Clinical update: intravenous iron for anaemia. Lancet. 2007 May 05; 369(9572):1502-1504. Auerbach M, Ballard H, Glaspy J. PMID: 17482969.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    75. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. PMID: 17434437.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    76. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007 Mar 06; 8:8. Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. PMID: 17341293.
      View in: PubMed   Mentions: 5     Fields:    
    77. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006 Aug 01; 12(15):4662-70. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. PMID: 16899616.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    78. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. Oncology (Williston Park). 2006 Jul; 20(8 Suppl 6):29-32. Glaspy J. PMID: 16925109.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7. 20030125 Study Group Trial , Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. PMID: 16710026.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    80. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. PMID: 16585569.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCellsPHPublic Health
    81. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006 Jan 01; 106(1):223-33. Lyman GH, Glaspy J. PMID: 16331597.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    82. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. PMID: 16397031.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    83. Cancer patient survival and erythropoietin. J Natl Compr Canc Netw. 2005 Nov; 3(6):796-804. Glaspy JA. PMID: 16316615.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    84. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. PMID: 16204013.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCellsCTClinical Trials
    85. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 Oct 01; 3(1):36-46. Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H. PMID: 18632435.
      View in: PubMed   Mentions:
    86. Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. Support Cancer Ther. 2005 Oct 01; 3(1):16-20. Glaspy JA. PMID: 18632430.
      View in: PubMed   Mentions:
    87. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS. PMID: 16133107.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    88. The development of erythropoietic agents in oncology. Expert Opin Emerg Drugs. 2005 Aug; 10(3):553-67. Glaspy JA. PMID: 16083329.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    89. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. PMID: 15775996.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    90. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005 May; 41(8):1140-9. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G, Darbepoetin Alfa 20010162 Study Group . PMID: 15911237.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    91. Entering a new era in the management of tumor-associated involution. J Support Oncol. 2005 Jan-Feb; 3(1):51-2. Glaspy JA. PMID: 15724945.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics. 2005; 23(5):505-14. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. PMID: 15896101.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    93. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology. 2005; 69 Suppl 2:8-16. Glaspy J, Beguin Y. PMID: 16244505.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    94. Novel interactions of vitamin E and estrogen in breast cancer. Nutr Cancer. 2005; 52(1):43-8. Chamras H, Barsky SH, Ardashian A, Navasartian D, Heber D, Glaspy JA. PMID: 16091003.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    95. Phase III clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol. 2005; 18(3):407-16. Glaspy J. PMID: 15792914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    96. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. PMID: 15314544.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    97. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004 Aug; 25(4):400-7. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR. PMID: 15296814.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    98. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. PMID: 15067052.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    99. Can erythropoietin therapy improve survival? Oncology. 2004; 67 Suppl 1:5-11. Glaspy J, Dunst J. PMID: 15486447.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    100. Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. Oncology (Williston Park). 2003 Dec; 17(12):1724-30; discussion 1731-2, 1735, 1739. Glaspy JA. PMID: 14723012.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5902-8. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. PMID: 14676113.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    102. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Oncology (Williston Park). 2003 Nov; 17(11):1593-603. Glaspy JA. PMID: 14682110.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    103. Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy. Support Cancer Ther. 2003 Oct 01; 1(1):49-54. Smith JR, Glaspy JA, Tchekmedyian NS, Austin MD, Kallich JD. PMID: 18628131.
      View in: PubMed   Mentions:
    104. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003 Jun 15; 21(12):2415-32. Ribas A, Butterfield LH, Glaspy JA, Economou JS. PMID: 12805342.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimals
    105. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003 Jun; 25(6):1786-805. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. PMID: 12860499.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    106. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma Res. 2003 Jun; 13(3):307-11. O'Day SJ, Agarwala SS, Naredi P, Kass CL, Gehlsen KR, Glaspy J. PMID: 12777988.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    107. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003 May-Jun; 10(3):715-24. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. PMID: 12684649.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    108. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. PMID: 12637463.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    109. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003 Mar 01; 97(5):1312-20. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. PMID: 12599240.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    110. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar; 9(3):998-1008. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. PMID: 12631598.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCellsCTClinical Trials
    111. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1751-6. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. PMID: 12578976.
      View in: PubMed   Mentions: 167     Fields:    Translation:AnimalsCells
    112. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003 Feb; 3(6):391-8. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T, Pegfilgrastim Study Group . PMID: 12636878.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    113. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer. 2003 May; 11(5):304-12. Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K, Agarwala SS. PMID: 12720074.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    114. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem. 2002 Dec; 13(12):711-716. Chamras H, Ardashian A, Heber D, Glaspy JA. PMID: 12550055.
      View in: PubMed   Mentions: 37     Fields:    
    115. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 2002 Nov; 9(11):875-83. Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS. PMID: 12386826.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    116. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem. 2002 Nov; 48(11):2057-9. Catlin DH, Breidbach A, Elliott S, Glaspy J. PMID: 12406997.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    117. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):23-9. Glaspy JA, Tchekmedyian NS. PMID: 12435170.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    118. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):45-55. Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. PMID: 12435173.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    119. The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):35-40. Glaspy JA. PMID: 12380953.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    120. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):71-7. Glaspy JA. PMID: 12380957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    121. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15; 95(4):888-95. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. PMID: 12209734.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    122. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002 Aug 01; 95(3):613-23. Langer CJ, Choy H, Glaspy JA, Colowick A. PMID: 12209755.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002 Jul 29; 87(3):268-76. Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB. PMID: 12177793.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    124. Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol. 2002 Jul; 42(7):774-81. Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S, Cosford R, Gehlsen K. PMID: 12092744.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    125. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002 Jun; 29(3 Suppl 7):41-6. Glaspy JA. PMID: 12068388.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    126. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol. 2002 Apr; 30(4):374-80. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. PMID: 11937274.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    127. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J. PMID: 12020395.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    128. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002 Feb; 2(1):57-78. Ribas A, Butterfield LH, Glaspy JA, Economou JS. PMID: 12108974.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    129. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. PMID: 14662041.
      View in: PubMed   Mentions: 2     Fields:    
    130. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7(2):126-35. Glaspy J, Degos L, Dicato M, Demetri GD. PMID: 11961196.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    131. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. PMID: 11773161.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    132. Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Cancer. 2002; 42(2):180-5. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Bagga D, Anders KH, Wang HJ, Glaspy JA. PMID: 12416257.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    John's Networks
    Concepts (480)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (48)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-866-g4098221c on PROFILES-PWEB02.

    Copyright © The Regents of the University of California